Press Releases

Filter: Year:

Compugen Appoints Senior Vice President Corporate and Business Development

Dec 05, 2016
READ MORE

Compugen to Present at 28th Annual Piper Jaffray Healthcare Conference in New York

Nov 21, 2016
READ MORE

Compugen Immune Checkpoint Program Demonstrates Potential for Development of New Cancer Immunotherapy Treatments

New preclinical results for CGEN-15029 presented in late-breaking session at Annual Meeting of the Society for Immunotherapy of Cancer

Nov 11, 2016
READ MORE

Compugen Ltd. Reports 3rd Quarter 2016 Financial Results

Quarterly conference call will be held on November 16, 2016

Nov 07, 2016
READ MORE

Compugen to Host R&D Day on December 7, 2016 in New York

Event to focus on the Company’s immuno-oncology programs

Nov 03, 2016
READ MORE

Compugen Third Quarter Financial Statements to be Released November 7, 2016

Third quarter conference call postponed to November 16 to allow discussion of new CGEN-15029 data to be presented at the Annual Meeting of the Society for Immunotherapy of Cancer

Oct 10, 2016
READ MORE

Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month

Presentation will include new data on CGEN-15029, a Compugen-discovered novel immune checkpoint target, including functional characterization and antibody blockade

Oct 07, 2016
READ MORE

Compugen Discloses Development of Enhanced LINKS Platform Utilized for the Discovery of Myeloid Targets for Cancer Immunotherapy

Myeloid target candidates predicted in silico using enhanced LINKS platform are now being experimentally validated

Aug 30, 2016
READ MORE

Compugen Ltd. Reports 2nd Quarter 2016 Financial Results

Aug 02, 2016
READ MORE

Compugen Second Quarter 2016 Conference Call Scheduled for Tuesday, August 2, 2016 at 10:00 AM ET

Jul 21, 2016
READ MORE

Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program

IND filing for COM701 anticipated next year

Jun 22, 2016
READ MORE

Compugen to Present at JMP Securities Life Sciences Conference in New York

Jun 15, 2016
READ MORE

Compugen to Present at the Jefferies Global Healthcare Conference in New York

May 23, 2016
READ MORE

Compugen to Present at the Oppenheimer Annual Israeli Conference in Tel Aviv

May 16, 2016
READ MORE

Compugen Ltd. Reports First Quarter 2016 Financial Results

May 10, 2016
READ MORE

Steven Holtzman Joins Compugen as Strategic Business Advisor

May 10, 2016
READ MORE

Compugen First Quarter 2016 Conference Call and Webcast Scheduled for Tuesday, May 10, 2016 at 10:00 AM ET

Apr 27, 2016
READ MORE

Compugen Achieves Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer

Compugen Achieves Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer

Apr 18, 2016
READ MORE

Dr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew Pardoll Appointed Director at Compugen USA, Inc.

Dr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew Pardoll Appointed Director at Compugen USA, Inc.

Apr 07, 2016
READ MORE

Compugen to Present at the Jefferies Immuno-Oncology Summit in Boston

Mar 28, 2016
READ MORE

Compugen Presents Results for CGEN-15029 Immuno-Oncology Therapeutic Program

Multiple blocking antibodies discovered for Compugen novel immune checkpoint target candidate for treatment of cancer

Feb 29, 2016
READ MORE

Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results

Feb 09, 2016
READ MORE

Compugen Fourth Quarter and Yearend 2015 Conference Call Scheduled for Tuesday, February 9, 2016 at 10:00 AM EST

Jan 26, 2016
READ MORE

Compugen Achieves Third Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer

Dec 11, 2015
READ MORE

Compugen to Present at the Oppenheimer Healthcare Conference in New York

Nov 24, 2015
READ MORE

Compugen to Present at Jefferies 2015 Global Healthcare Conference in London

Nov 12, 2015
READ MORE

Compugen Presents Translational Study Results Supporting CGEN-15001 for the Treatment of Rheumatoid Arthritis

Results of research collaboration with Prof. Iain B. McInnes from Glasgow University presented at the American College of Rheumatology Annual Meeting

Nov 09, 2015
READ MORE

Compugen Ltd. Reports 3rd Quarter 2015 Financial Results

Nov 03, 2015
READ MORE

Compugen Third Quarter 2015 Conference Call Scheduled for Tuesday, November 3, 2015 at 10:00 AM ET

Oct 27, 2015
READ MORE

Compugen Discloses Antibody Drug Conjugate Program Results at the World ADC Summit in San Diego

Oct 19, 2015
READ MORE

Compugen Discloses New Results Supporting CGEN-15052 as Novel Immune Checkpoint Target Candidate for Treatment of Cancer

Data presented at the Inaugural International Cancer Immunotherapy Conference in New York City

Sep 16, 2015
READ MORE

Compugen to Present at Upcoming Immuno-Oncology and Rheumatology Conferences

Sep 09, 2015
READ MORE

Compugen Ltd. Reports 2nd Quarter 2015 Financial Results

Aug 04, 2015
READ MORE

Compugen Second Quarter 2015 Conference Call Scheduled for Tuesday, August 4, 2015 at 10:00 AM ET

Jul 27, 2015
READ MORE

Compugen to Present at JMP Securities Life Sciences Conference in New York

Jun 15, 2015
READ MORE

Compugen to Disclose Novel Cancer Immunotherapy Target Candidate and Comprehensive Target Characterization Infrastructure at Today’s Analyst and Investor Day

CGEN-15029 target candidate is one of Compugen’s five highest priority cancer immunotherapy target programs

Jun 08, 2015
READ MORE

Compugen to Present at Jefferies 2015 Global Healthcare Conference in New York

May 28, 2015
READ MORE

Compugen to Hold Analyst and Investor Day in New York

A live webcast of the presentations will be available via the Company’s website

May 27, 2015
READ MORE

Compugen Ltd. Reports First Quarter 2015 Results

May 05, 2015
READ MORE

Compugen First Quarter 2015 Conference Call Scheduled for Tuesday, May 5, 2015 at 10:00 AM ET

Apr 28, 2015
READ MORE

Compugen Obtains Rights to Use Biological Systems and Materials from the US National Institutes of Health

Additional capabilities anticipated to enhance research and development of Compugen’s immuno-oncology programs

Apr 14, 2015
READ MORE

Compugen to Present at Two Immuno-Oncology Conferences in April

Apr 06, 2015
READ MORE

Compugen Announces Planned Relocation of Headquarters to Larger Facilities

New facilities double available space for corporate offices and research and discovery in Israel

Mar 19, 2015
READ MORE

Compugen to Present at Two Oncology Conferences in March

Presentations include experimental data demonstrating potential of Compugen-discovered novel immune checkpoints as targets for cancer immunotherapy

Mar 02, 2015
READ MORE

Compugen Expands and Strengthens Business Development Team

Felix Karim, PhD, joins Company as Vice President Corporate & Business Development

Feb 23, 2015
READ MORE

Compugen Ltd. Reports Fourth Quarter and Calendar 2014 Results

Feb 10, 2015
READ MORE

Compugen Presents New Results Supporting CGEN-15049 as Potential Cancer Immunotherapy Target

Data presented at the Keystone Symposia on Tumor Immunology

Feb 09, 2015
READ MORE

Compugen Fourth Quarter and Yearend 2014 Conference Call Scheduled for Tuesday, February 10, 2015 at 10:00 AM EST

Feb 03, 2015
READ MORE

Compugen to Present Cancer Immunotherapy Targets at Two Tumor Immunology Conferences This Month

Feb 02, 2015
READ MORE

Compugen Discloses Initial Experimental Results for Predicted Antibody Drug Conjugate Targets

Pipeline Program for oncology to be further expanded and diversified with addition of ADC therapeutic programs to ongoing immuno-oncology programs

Jan 05, 2015
READ MORE

Compugen Enters Immuno-Oncology Research Collaboration with Johns Hopkins University

Dec 18, 2014
READ MORE

Compugen to Present at Oppenheimer 25th Annual Healthcare Conference

Dec 03, 2014
READ MORE

Compugen Announces Experimental Confirmation of Additional Methodology for Discovery of Cancer-Related Immune Checkpoints

Dec 02, 2014
READ MORE

Compugen to Present at Jefferies 2014 Global Healthcare Conference in London

Nov 12, 2014
READ MORE

Compugen Ltd. Reports Third Quarter 2014 Financial Results

Oct 29, 2014
READ MORE

Compugen Discloses Successful Validation Results for Novel B7/CD28-like Cancer Immunotherapy Target Candidate

Oct 27, 2014
READ MORE

Compugen Third Quarter 2014 Conference Call Scheduled for Wednesday, October 29, 2014 at 10:00 AM ET

Oct 22, 2014
READ MORE

Compugen Achieves Second Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer

Oct 14, 2014
READ MORE

Compugen Immune Checkpoint Results Being Presented at Three Scientific Conferences

Oct 06, 2014
READ MORE

Compugen Discloses New Results for Novel Target Candidate for Cancer Immunotherapy

Oct 01, 2014
READ MORE

Compugen Announces Presentations of Results for CGEN-15001 Supporting Immune Tolerance Induction

Sep 29, 2014
READ MORE

Compugen Appoints Mr. Ari Krashin as Chief Financial Officer

Aug 25, 2014
READ MORE

Compugen Reacquires Baize's Financial Interest in Pipeline Product Candidates

Aug 21, 2014
READ MORE

Compugen Ltd. Reports 2nd Quarter 2014 Financial Results

Aug 06, 2014
READ MORE

Compugen Second Quarter 2014 Conference Call Scheduled for Wednesday, August 6, 2014 at 10:00 AM EDT

Jul 31, 2014
READ MORE

Compugen to Present Immune Checkpoint Related Research at Two Scientific Conferences

Jul 24, 2014
READ MORE

Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins

Jul 14, 2014
READ MORE

Compugen Discloses Achievement of Milestone in Cancer Immunotherapy Collaboration with Bayer

Jul 07, 2014
READ MORE

Compugen Discloses Experimental Results for Novel Checkpoint Candidate for Cancer Immunotherapy and Discovery of Two New Candidates

Jun 16, 2014
READ MORE

Compugen Ltd. Reports First Quarter 2014 Results

May 19, 2014
READ MORE

Compugen Appoints Mr. Avihai Shen Interim CFO

May 12, 2014
READ MORE

Compugen First Quarter 2014 Conference Call Scheduled for Monday, May 19, 2014 at 10:00 AM EST

May 07, 2014
READ MORE

Compugen to Present at Immunology 2014 Conference

Apr 29, 2014
READ MORE

Compugen Statement Regarding Insider Trading Allegations

Apr 08, 2014
READ MORE

Compugen Ltd. Closes Public Offering of Ordinary Shares

Mar 06, 2014
READ MORE

Compugen Ltd. Prices Public Offering of Ordinary Shares

Mar 02, 2014
READ MORE

Compugen to Present Cancer Immunotherapy Programs at Three International Cancer Conferences in March

Feb 20, 2014
READ MORE

Compugen Ltd. Reports Fourth Quarter and Calendar 2013 Results

Feb 11, 2014
READ MORE

Compugen Fourth Quarter and Yearend 2013 Conference Call Scheduled for Tuesday, February 11, 2014 at 10:00 AM EST

Feb 04, 2014
READ MORE

Compugen to Present Predictive Methodology for Discovery of Novel Immune Checkpoints at the Washington BioLeaders Forum

Jan 22, 2014
READ MORE

Compugen Announces Addition of Prof. Drew Pardoll to Its Scientific Advisory Board

Jan 21, 2014
READ MORE

Compugen to Significantly Expand Immuno-Oncology Activities During 2014

Jan 07, 2014
READ MORE

Compugen Discloses Discovery of Five Potential Cancer Targets for Antibody Drug Conjugate Therapy

Dec 11, 2013
READ MORE

Compugen Ltd. Reports Third Quarter 2013 Financial Results

Oct 30, 2013
READ MORE

Compugen Third Quarter 2013 Conference Call Scheduled for Tuesday, October 29, 2013 at 10:00 AM EST

Oct 22, 2013
READ MORE

Compugen Presents Experimental Results Supporting Induction of Immune Tolerance by CGEN-15001 Drug Candidate

Oct 16, 2013
READ MORE

Compugen Drug Candidate Demonstrates High Effectiveness in Type I Diabetes Animal Model

Oct 09, 2013
READ MORE

Compugen Target for Cancer Immunotherapy Shown to Affect Multiple Immune Cell Types Involved in Tumor Progression

Sep 22, 2013
READ MORE

Compugen Establishes Scientific Advisory Board

Aug 27, 2013
READ MORE

Compugen Announces Collaboration and License Agreement with Bayer for Antibody-Based Cancer Immunotherapies

Compugen to hold 2nd Quarter Conference Call August 7, 2013

Aug 05, 2013
READ MORE

Compugen Second Quarter 2013 Conference Call Scheduled for Wednesday, August 7, 2013 at 10:00 AM EDT

Aug 05, 2013
READ MORE

Compugen Discloses Predictive Structural Biology Infrastructure Platform for Enhanced Discovery of Novel Drugs

Jul 17, 2013
READ MORE

Compugen Announces US Patent Allowance for Drug Candidate Recently Presented at 2013 American Thoracic Society Meeting

Jul 16, 2013
READ MORE

Compugen to Present at Jefferies 2013 Global Healthcare Conference

May 28, 2013
READ MORE

Compugen Ltd. Reports First Quarter 2013 Financial Results

Apr 25, 2013
READ MORE

Compugen First Quarter 2013 Conference Call Scheduled for Thursday, April 25, 2013 at 10:00 AM EST

Apr 22, 2013
READ MORE

Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy

Apr 02, 2013
READ MORE

Compugen Ltd. Reports Fourth Quarter and Calendar 2012

Feb 20, 2013
READ MORE

Compugen to Present at the Molecular Medicine Tri-Conference 2013 in San Francisco

Feb 06, 2013
READ MORE

Compugen Presents at American Association of Cancer Research Special Conference on Tumor Immunology

Dec 05, 2012
READ MORE

Compugen Announces $15 Million Funding Agreement for Its Keddem Subsidiary

Nov 20, 2012
READ MORE

Compugen to Present at Jefferies 2012 Global Healthcare Conference

Nov 14, 2012
READ MORE

Compugen Ltd. Reports Third Quarter 2012 Financial Results

Nov 05, 2012
READ MORE

Compugen Announces Discovery of Two Novel Immune Checkpoint Targets for Cancer Immunotherapy

Nov 04, 2012
READ MORE

Compugen Postpones Issuance of Third Quarter 2012 Report and Associated Conference Call to November 5, 2012

Oct 30, 2012
READ MORE

Compugen Drug Candidate Demonstrates Attenuation of Autoimmunity and Reestablishment of Immune Balance

Sep 10, 2012
READ MORE

Compugen Ltd. Reports Second Quarter 2012 Financial Results

Aug 07, 2012
READ MORE

Compugen Announces Development of NexGen Infrastructure Platform for Analysis of Next Generation Sequencing Data

Jul 02, 2012
READ MORE

Compugen Announces Validation Results for a Second Potential Immune Checkpoint Target for Cancer Immunotherapy

Jun 27, 2012
READ MORE

Compugen and Merck Serono Ventures to Jointly Establish New Biomarker Company Neviah Genomics Ltd.

Jun 25, 2012
READ MORE

Compugen Ltd. Reports First Quarter 2012 Financial Results

May 01, 2012
READ MORE

Compugen Announces Initial Validation Results for Two Novel Immunomodulatory Proteins and Further Results for CGEN-15001

Apr 24, 2012
READ MORE

Compugen Establishes Operations in California for Development of Monoclonal Antibody Drug Candidates

Mar 28, 2012
READ MORE

Compugen Presents Prediction Based Discovery Strategy

Feb 27, 2012
READ MORE

Compugen Ltd. Reports Fourth Quarter and Calendar 2011 Financial Results

Feb 07, 2012
READ MORE

Compugen to Present at the BIO CEO & Investor Conference 2012

Feb 06, 2012
READ MORE

Compugen Fourth Quarter 2011 Conference Call Scheduled for Tuesday, February 7, 2012 at 10:00 AM EST

Feb 05, 2012
READ MORE

Compugen Presents Three Product Candidates for Treatment of Autoimmune Diseases at the Immunotherapeutics & Immunomonitoring Conference

Jan 30, 2012
READ MORE

Compugen to Broaden and Accelerate Monoclonal Antibody Program for Oncology and Immunology

Dec 20, 2011
READ MORE

BioLineRx to Develop and Commercialize Novel Peptides

Dec 14, 2011
READ MORE

Compugen Presents Predictive Drug Target Discovery Platform at European Antibody Conference

Nov 30, 2011
READ MORE

Compugen and DiscoveRx Form Collaboration to Commercialize Novel Peptide Ligands for GPCR Drug Targets

Nov 29, 2011
READ MORE

Compugen Reports Third Quarter 2011 Financial Results

Nov 10, 2011
READ MORE

Martin Gerstel, Chairman, interviewed on Bloomberg TV

Nov 07, 2011
READ MORE

Compugen's CGEN-15001 Pre-Clinical Data Presented at International Conference on Immune Tolerance

Oct 25, 2011
READ MORE

Pulmonary Fibrosis Foundation to Fund Further Therapeutic Evaluation Studies for Compugen-Discovered Drug Candidate

Oct 12, 2011
READ MORE

Compugen Announces Validation of Two Immune System Modulating Drug Candidates

Sep 13, 2011
READ MORE

Compugen Reports Second Quarter 2011 Financial Results

Aug 02, 2011
READ MORE

Compugen Second Quarter 2011 Conference Call Scheduled for Tuesday, August 2, 2011 at 10:00 AM EDT

Jul 21, 2011
READ MORE

Compugen Announces Initial Validation of Additional B7/CD28 Protein Family Based Product Candidate

Jun 21, 2011
READ MORE

Compugen Discloses Discovery Method for Drug Candidates That Interfere With Protein Conformations

May 19, 2011
READ MORE

Compugen Reports First Quarter 2011 Financial Results

May 11, 2011
READ MORE

Compugen First Quarter 2011 Webcast and Conference Call Scheduled for Wednesday, May 11, 2011 at 10:00 AM EDT

May 03, 2011
READ MORE

Compugen Discloses Splice Variant Based Program to Discover Superior Oncology Drug Targets for mAb Therapy

Apr 27, 2011
READ MORE

Compugen Announces Positive Animal Model Results for Novel Peptide Predicted to Block Protein-Protein Interaction

Mar 07, 2011
READ MORE

Compugen Ltd. Reports Fourth Quarter and Calendar 2010 Financial Results

Feb 15, 2011
READ MORE

Compugen Ltd. to Review Fourth Quarter and Year-End 2010 Financial Results on Tuesday, February 15, 2011

Feb 08, 2011
READ MORE

Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy

Feb 02, 2011
READ MORE

Compugen Signs $5 Million R&D Funding Agreement in Support of its Pipeline Program

Dec 30, 2010
READ MORE

Compugen Announces Positive Therapeutic Effect of CGEN-15001 in Animal Model of Rheumatoid Arthritis

Dec 14, 2010
READ MORE

New Studies Support Therapeutic Potential of Compugen Discovered Target for Multiple Myeloma Treatment

Dec 06, 2010
READ MORE

Compugen Announces Discovery Platform for New Members of Protein Families with Known Therapeutic Applications

Nov 22, 2010
READ MORE

Compugen Licenses Novel Oncology Target to Seattle Genetics

Oct 29, 2010
READ MORE

Compugen Reports Third Quarter 2010 Financial Results

Oct 26, 2010
READ MORE

Compugen Ltd. to Review Third Quarter 2010 Financial Results on Tuesday, October 26, 2010

Oct 19, 2010
READ MORE

Compugen Reports Second Quarter 2010 Financial Results

Jul 27, 2010
READ MORE

Compugen Second Quarter 2010 Webcast and Conference Call Scheduled for Tuesday, July 27, 2010 at 10:00 AM EDT

Jul 23, 2010
READ MORE

Compugen Discovered Protein Shown to Abolish Recurring Relapses in Multiple Sclerosis Animal Model

Jul 01, 2010
READ MORE

Compugen Discovers Drug Target for Treatment of Multiple Myeloma

May 11, 2010
READ MORE

Compugen to Host Q&A Conference Call on Wednesday, May 5, 2010 at 10:00 AM EDT

May 03, 2010
READ MORE

Compugen Reports First Quarter 2010 Financial Results

Apr 27, 2010
READ MORE

Compugen Announces New Drug Discovery Platform to Predict Peptides that Block Protein - Protein Interactions

Apr 22, 2010
READ MORE

Compugen Announces Discovery Platform to Predict Cell Penetrating Peptides for Drug Delivery

Mar 16, 2010
READ MORE

Compugen Appoints Dr. Anat Cohen-Dayag as President and CEO

Mar 02, 2010
READ MORE

Compugen Ltd. Reports Fourth Quarter and Calendar 2009 Financial Results

Feb 09, 2010
READ MORE

Compugen Discovers Novel Protein for Treatment of Autoimmune Diseases

Feb 02, 2010
READ MORE

Compugen Raises Gross Proceeds of $20 Million Through Sale of Ordinary Shares

Dec 30, 2009
READ MORE

Compugen Discovers Drug Target for Treatment of Epithelial Tumors

Dec 28, 2009
READ MORE

Compugen Announces "Discovery on Demand" Therapeutic Peptide Collaboration with Pfizer

Dec 23, 2009
READ MORE

Compugen Announces Discovery of Genetic Biomarker for Predisposition to Type 2 Diabetes

Nov 09, 2009
READ MORE

Compugen Announces Preeclampsia Biomarker Collaboration

Nov 05, 2009
READ MORE

Compugen Reports Third Quarter 2009 Financial Results

Oct 27, 2009
READ MORE

Compugen Presents DAC Blockers Platform and Initial Product Candidates at Fifth Peptide Engineering Meeting in Barcelona, Spain

Oct 26, 2009
READ MORE

Compugen and Bayer Schering Pharma to Collaborate on Compugen Discovered Oncology Target and Splice Variants

Oct 13, 2009
READ MORE

Compugen Reports Second Quarter 2009 Results

Jul 28, 2009
READ MORE

Compugen Announces Positive Therapeutic Effects of Novel Peptide in Animal Model of Retinopathy

Jul 21, 2009
READ MORE

Compugen Reports Sale of a Portion of its Evogene Holdings

Jun 30, 2009
READ MORE

Compugen Announces Additional Grants from Israel Office of Chief Scientist for Validation Studies of Therapeutic Candidates

Jun 24, 2009
READ MORE

Compugen Announces Positive Therapeutic Effects of Novel Peptide in Animal Model of Inflammatory Bowel Disease

Jun 23, 2009
READ MORE

Compugen Transfers to The NASDAQ Capital Market

Jun 17, 2009
READ MORE

Compugen Awarded Grants from Israel Office of Chief Scientist

Jun 03, 2009
READ MORE

Compugen Appoints Dr. Anat Cohen-Dayag and Martin Gerstel as Co-CEOs

Jun 02, 2009
READ MORE

Compugen Receives Deficiency Letter from NASDAQ With Respect to Stockholders Equity

Jun 02, 2009
READ MORE

Teva to Utilize Compugen-Discovered Biomarkers for Pre-Clinical Detection of Drug-induced Kidney Toxicity

May 24, 2009
READ MORE

Compugen Announces In Vivo Confirmation of Cardiovascular Therapeutic Potential for Two Novel Peptides

May 14, 2009
READ MORE

Compugen Reports First Quarter 2009 Financial Results

May 12, 2009
READ MORE

Compugen Predictive Discovery Capabilities Presented by CTO at Bio-IT Conference and Expo 2009

Apr 29, 2009
READ MORE

Compugen Announces Inhibition of Angiogenesis by Novel Peptide

Apr 01, 2009
READ MORE

Compugen Announces Positive Therapeutic Effects of Relaxin Receptor Peptide Ligand in Pulmonary Fibrosis Animal Model

Mar 17, 2009
READ MORE

Compugen Ltd. Reports Fourth Quarter and Year-End 2008 Financial Results

Feb 11, 2009
READ MORE

Compugen Appoints Dov Hershberg Chairman of the Board

Feb 09, 2009
READ MORE

Compugen Announces Discovery of Biomarker Candidate for Diagnosis of Ovarian Cancer and Signing of Collaboration Agreement

Feb 03, 2009
READ MORE

Compugen and Merck Serono to Collaborate on Novel Peptide

Nov 26, 2008
READ MORE

Compugen Reports Third Quarter 2008 Financial Results

Nov 13, 2008
READ MORE

Compugen Appoints Martin Gerstel CEO Effective January 2009

Nov 12, 2008
READ MORE

Compugen Chairman Presents Company Overview and Plans for 2009 at Rodman & Renshaw Healthcare Conference

Nov 12, 2008
READ MORE

Compugen Announces New Discovery Platform to Identify Viral Peptides for Use as Human Anti Inflammatory Drugs

Oct 23, 2008
READ MORE

Compugen Has No Intention of Issuing Equity at Current Market Value

Oct 05, 2008
READ MORE

Compugen Discovers Peptide Drug Candidate for Treatment of Solid Tumor Cancers and Announces Positive In Vivo Results

Sep 16, 2008
READ MORE

Compugen Retains Porter Novelli Life Sciences for U.S. Corporate Communications Initiative

Sep 09, 2008
READ MORE

Compugen Reports Second Quarter 2008 Results

Jul 29, 2008
READ MORE

Compugen Planning Proof of Concept Human Trial for Breast Cancer Drug Candidate in 2009

Jul 16, 2008
READ MORE

Compugen Announces Positive In-Vivo Results for Therapeutic Peptide Candidate for Immune Related Diseases

Jul 09, 2008
READ MORE

Compugen Announces Discovery of Biomarkers for Early Pre-Clinical Detection of Drug-induced Kidney Toxicity

Jun 26, 2008
READ MORE

Compugen Announces Discovery of Novel Drug Targets for Cancer Antibody Therapeutics

Jun 11, 2008
READ MORE

Compugen Ltd. to Highlight Company's Therapeutic Platforms at BioMed Israel 2008

May 26, 2008
READ MORE

Compugen Presents Experimental Results for Three G-Protein Coupled Receptor (GPCR) Ligands

May 20, 2008
READ MORE

Compugen Reports First Quarter 2008 Results

May 14, 2008
READ MORE

Compugen First Quarter 2008 Conference Call to be held 10:00 AM EDT Wednesday, May 14, 2008

May 06, 2008
READ MORE

Compugen Announces Discovery of Blood Based Biomarker for Diagnosis of Lung Cancer

Apr 29, 2008
READ MORE

Compugen Discloses Novel Troponin Variant for Identification of Cardiac Muscle Injury, Receipt of Patent for the Molecule and Collaboration with Biosite

Apr 01, 2008
READ MORE

Compugen Announces New Drug Discovery Platform to Predict Peptides that Block Disease-Associated Conformations of Proteins

Mar 18, 2008
READ MORE

Compugen Ltd. Reports Fourth Quarter and Year-End 2007 Financial Results

Feb 19, 2008
READ MORE

Compugen Announces In-Vivo Results for Two Novel Peptide Agonists of MAS GPCR for Potential Treatment of Cardiovascular Pathologies

Feb 12, 2008
READ MORE

Compugen Announces In-Vivo Results for Two Peptide Anti-Inflammatory and Cardio-Protective Drug Candidates

Jan 29, 2008
READ MORE

Compugen Announces GPCR Ligand Discovery and License Option Agreement with Merck

Jan 14, 2008
READ MORE

Compugen and Roche sign Agreement to Identify Genetic Variations Predictive of Drug Response in Rheumatoid Arthritis Patients

Dec 20, 2007
READ MORE

Compugen Reports Third Quarter 2007 Financial Results

Oct 23, 2007
READ MORE

Compugen Announces Agreement with Teva Covering Splice Variant of MCP1 for Treatment of Chronic Inflammatory Diseases

Aug 28, 2007
READ MORE

Compugen Reports Second Quarter 2007 Financial Results

Aug 02, 2007
READ MORE

Compugen Adds Three Members to Board of Directors

Aug 01, 2007
READ MORE

Compugen Announces Discovery Engine for Identifying Existing Drugs with Predicted New Indications

Jul 31, 2007
READ MORE

Compugen Ltd. to Review Second Quarter 2007 Results on Thursday, August 2, 2007

Jul 26, 2007
READ MORE

Compugen To Present at Drug Discovery Chemistry 2007

May 14, 2007
READ MORE

Compugen Reports First Quarter 2007 Financial Results

May 01, 2007
READ MORE

Compugen Announces Appointment of Ronit Lerner as Chief Financial Officer and Rachel Bart as General Counsel

Apr 30, 2007
READ MORE

Compugen Announces Collaboration for the Discovery of Novel Biomarkers for Unstable Atherosclerotic Plaques

Apr 30, 2007
READ MORE

Compugen Announces Second Diagnostic Agreement with Biosite Incorporated

Mar 07, 2007
READ MORE

Compugen Announces Discovery of Eight Novel G-Protein Coupled Receptor (GPCR) Peptide Ligands

Feb 20, 2007
READ MORE

Compugen to Present Experimental Data for its Novel Splice Variant of c-Met Receptor

Feb 08, 2007
READ MORE

Compugen Ltd. Reports Fourth Quarter and Year-End 2006 Financial Results

Feb 06, 2007
READ MORE

Compugen Ltd. to Review Fourth Quarter and Full Year 2006 Results on Tuesday, February 6, 2007

Feb 01, 2007
READ MORE

Compugen to Collaborate with Teva for Discovery of Novel Biomarkers for Drug Toxicity

Jan 30, 2007
READ MORE

Compugen to Present Experimental Data of its MCP-1 Antagonist Candidate at GTCBio's Cytokines and Inflammation Conference

Jan 29, 2007
READ MORE

Medarex and Compugen Announce Therapeutic Antibody Co-Development Agreement

Jan 23, 2007
READ MORE

Compugen to Participate in Diagnostics Panel at RBC Capital Markets 2006 Healthcare Conference

Dec 12, 2006
READ MORE

Compugen Launches Predictive Discovery Platform with 200,000 Novel Genomic Variations

Nov 15, 2006
READ MORE

Compugen Appoints Eli Zangvil, MD, as Vice President Business Development

Nov 07, 2006
READ MORE

Compugen to Present at the Unterberg, Towbin Life Sciences Conference

Oct 26, 2006
READ MORE

Compugen Reports Third Quarter 2006 Financial Results

Oct 25, 2006
READ MORE

Compugen Discloses Status of In Silico Discovered Therapeutic Candidates

Oct 19, 2006
READ MORE

Compugen to Present at the BIO InvestorForum 2006

Oct 17, 2006
READ MORE

Compugen Reports Second Quarter 2006 Financial Results

Jul 26, 2006
READ MORE

Compugen to Present at the 2006 C.E. Unterberg Towbin Emerging Growth Opportunities Conference

Jul 10, 2006
READ MORE

Compugen Reports First Quarter 2006 Financial Results

Apr 27, 2006
READ MORE

Compugen to Present at the BIO CEO & Investor Conference 2006

Mar 13, 2006
READ MORE

Compugen Leads Consortium to Model Cancer Related Kinase Pathway

Mar 07, 2006
READ MORE

Compugen to Present at the SG Cowen & Co. 26th Annual Health Care Conference

Mar 01, 2006
READ MORE

Compugen Announces In-Silico Protein Discovery from "Junk DNA"

Feb 14, 2006
READ MORE

Compugen Ltd. Reports Fourth Quarter and Year-End 2005 Financial Results

Feb 09, 2006
READ MORE
Dec 07, 2016

CGEN R&D Day 2016

NYC
MORE EVENTS
Banner